Palatin Technologies to List on Nasdaq Capital Market Starting May 29, 2026
PTN•Palatin Technologies will transfer its common stock from NYSE American to the Nasdaq Capital Market, commencing trading under the symbol PTN on May 29, 2026, after the May 28 market close. The move aims to boost share visibility, enhance trading liquidity and attract institutional investors.
1. Listing Transfer to Nasdaq Capital Market
Palatin Technologies has received approval to transfer its common stock listing from NYSE American to the Nasdaq Capital Market. Trading under the symbol PTN will begin on May 29, 2026, following the close of trading on May 28, with no action required by current shareholders.
2. Strategic Benefits of the Move
The company expects the Nasdaq listing to enhance the visibility of its shares, improve trading liquidity and expand exposure to institutional investors. CEO Carl Spana highlighted that joining a leading biotechnology community on Nasdaq supports Palatin’s growth and investor outreach objectives.
3. Ongoing MC4R Therapeutics Programs
Palatin continues advancing its selective MC4R-based obesity pipeline, targeting rare disorders such as hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The injectable peptide agonist program targets an IND submission in Q4 2026, while the next-generation oral candidate is aimed for IND filing in H1 2027.
